FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA and RNA sequencing for patients with hematologic malignancies and solid tumors. FoundationOne Heme detects known, novel, and complex fusion events as well as other common genomic alterations (substitutions, indels, and CNVs).

If you will be sending peripheral whole blood or bone marrow aspirate to Foundation Medicine for testing with FoundationOne ® Liquid CDx or FoundationOne ® Heme, please follow the instructions below: Place a test order through your EMR if enabled or order online by logging in or signing-up for a Foundation Medicine

FoundationOne®Heme is a qualitative next-generation sequencing based laboratory developed test (LDT) for detection of substitutions, insertion and deletion alterations (indels), copy number alterations (CNAs), select gene rearrangements, and genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB).

FoundationOne®Heme is a comprehensive genomic profiling service for hematologic malignancies and sarcomas, providing insights to guide treatment decisions.

FoundationOne Heme For patients with hematologic malignancies, sarcomas or solid tumors where fusion detection is desired. FoundationOne Heme’s DNA and RNA sequencing provides sensitive detection of known, novel and complex fusion events. We also have one of the largest databases of sequenced sarcoma patients in the world. (>14K patients ...

2013年12月7日 · FoundationOne Heme uses comprehensive, clinical next-generation sequencing (NGS) to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in hematologic malignancies, as well as many sarcomas and pediatric cancers.

2025年2月18日 · BOSTON-- (BUSINESS WIRE)-- Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced a collaboration with Sumitomo Pharma America, Inc. (SMPA) to...

FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA and RNA sequencing for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel, and complex fusion events as well as other common genomic alterations (substitutions, indels, and CNVs).

2013年12月10日 · FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), as well as many sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer.

Fresh Specimens (Peripheral Whole Blood or Bone Marrow Aspirate) Ensure that you are utilizing the correct kit for the patient: Accepted tumor types for FoundationOne Heme Fresh kits are leukemias and lymphomas, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).